TD Cowen Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price target raised by TD Cowen from $261.00 to $268.00 in a research report sent to investors on Monday,Benzinga reports. TD Cowen currently has a hold rating on the insurance provider’s stock.

Several other research firms also recently issued reports on HUM. Barclays increased their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial lowered their price target on shares of Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a report on Friday, October 11th. KeyCorp began coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Finally, Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Humana currently has an average rating of “Hold” and an average target price of $315.86.

Humana Stock Down 0.3 %

Shares of NYSE:HUM opened at $287.76 on Monday. The business’s 50 day moving average is $291.98 and its 200 day moving average is $333.24. The stock has a market cap of $34.65 billion, a price-to-earnings ratio of 25.56, a PEG ratio of 1.98 and a beta of 0.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. On average, sell-side analysts forecast that Humana will post 16.15 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.23%. Humana’s payout ratio is 31.36%.

Institutional Investors Weigh In On Humana

A number of large investors have recently added to or reduced their stakes in HUM. Norden Group LLC boosted its stake in shares of Humana by 137.9% during the 1st quarter. Norden Group LLC now owns 1,130 shares of the insurance provider’s stock worth $392,000 after acquiring an additional 655 shares during the last quarter. Jennison Associates LLC purchased a new stake in Humana in the first quarter worth about $46,885,000. Buck Wealth Strategies LLC purchased a new position in shares of Humana during the 1st quarter valued at about $1,871,000. Mawer Investment Management Ltd. lifted its position in shares of Humana by 100.4% during the 1st quarter. Mawer Investment Management Ltd. now owns 24,089 shares of the insurance provider’s stock valued at $8,352,000 after buying an additional 12,066 shares in the last quarter. Finally, Ballast Inc. bought a new position in shares of Humana during the 1st quarter valued at approximately $666,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.